Background. When hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP) is caused by gram-positive and gram-negative pathogens or both (mixed infections), the adequacy of gram-negative coverage (GNC) can confound the assessment of a gram-positive agent under study. This analysis examines the influence of gram-negative infections and the adequacy of GNC on clinical efficacy and all-cause mortality in the telavancin HABP/VABP phase 3 ATTAIN trials (Assessment of Telavancin for Treatment of Hospital-Acquired Pneumonia).
Telavancin is a lipoglycopeptide injectable antibiotic that has potent in vitro activity against gram-positive bacteria, including methicillin-susceptible and methicillin-resistant Staphylococcus aureus. It was first approved by the US Food and Drug Administration in 2009 for the treatment of complicated skin and skin structure infections, and in 2013 it was approved for the treatment of hospitalacquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of S. aureus when alternative treatments are not suitable [1] . This most recent approval was based on 2 phase 3 studies, the ATTAIN trials (Assessment of Telavancin for Treatment of Hospital-Acquired Pneumonia) [2] . These identically designed trials assessed the clinical efficacy and safety of telavancin with that of vancomycin in the treatment of HABP/VABP due to gram-positive organisms, with a focus on infections caused by methicillin-resistant S. aureus.
Because HABP/VABP may be caused by multiple pathogens in mixed infections, including both grampositive and gram-negative pathogens, the adequacy of gram-negative coverage (GNC) can confound the assessment of the treatment effect of the gram-positive agent under study. This analysis was conducted to provide a further understanding of the difference observed in clinical cure and all-cause mortality observed between telavancin and vancomycin in the ATTAIN trials [2, 3] . Data regarding cause of death, infecting pathogens, and adequacy of GNC were examined and analyzed. The impact on clinical cure and 28-day mortality for those with gram-negative infection and adequacy of GNC was examined and compared for those infected with only gram-positive organisms.
METHODS

Study Design
This study was a post hoc analysis of outcomes data from 2 identical, randomized, double-blind, comparator-controlled, parallel-group, phase 3 ATTAIN clinical trials (study 0015, NCT00107952; study 0019, NCT00124020), including supplemental vital-status data obtained after study completion [2, 3] . The prespecified primary efficacy end point for these trials was clinical response at follow-up/test-of-cure visit as assessed by the investigator at 7-14 days after the end of therapy. Mortality assessment included additional patient follow-up to day 28 after randomization and has been described elsewhere [3] . Study enrollment in the ATTAIN trials occurred between January 2005 and June 2007.
Study Subjects
Male and nonpregnant female patients aged ≥18 years were eligible for enrollment if they had pneumonia acquired after 48 hours in an inpatient acute-care or chronic-care facility or developed within 7 days after discharge. This included hospitalized patients with VABP in whom pneumonia developed de novo after ≥48 hours of mechanical ventilation.
Analysis Population
The all-treated (AT) analysis population from the 2 identical ATTAIN studies comprised all randomized patients who received ≥1 dose of study medication. The safety analysis population included all patients from the AT population, assigned based on actual treatment received. Two patients who were randomized to receive vancomycin actually received telavancin; therefore, these patients are included in the safety population for telavancin and in the AT population for vancomycin.
Study Antibiotics
Eligible patients were randomized 1:1 to receive either telavancin 10 mg/kg intravenously every 24 hours or vancomycin 1 g intravenously every 12 hours for 7-21 days. The duration of therapy was modeled after the linezolid nosocomial pneumonia registrational trial [4] . The dose of telavancin was adjusted if the patient's creatinine clearance (CrCl) was ≤50 mL/min. Vancomycin dosage could be modified per site-specific procedures for body weight and/or renal function as well as vancomycin trough level monitoring, as long as the study blind was maintained.
Concomitant Antibiotics
Patients with suspected polymicrobial infections were allowed to receive concomitant aztreonam and/or metronidazole, or piperacillin-tazobactam per protocol. Dosing for these agents, as stated in the study protocol, was to be per the manufacturer's labeling. Because the study was designed to compare the safety and efficacy of 2 drugs with activity against gram-positive pathogens, the use of concomitant gram-negative therapy was left to the discretion of the investigator. Piperacillin-tazobactam may have been administered for GNC only if aztreonam was not appropriate due to documented resistance or there was an unacceptable level of resistance among gram-negative bacteria at the particular research site. However, because piperacillin-tazobactam has activity against methicillin-susceptible Staphylococcus aureus and Streptococcus pneumoniae, patients with those organisms who required >24 hours of treatment with this medication should not have been enrolled. For those patients already enrolled, whenever possible, piperacillin-tazobactam was to be discontinued or changed to aztreonam as soon as feasible, as stated in the protocol. Finally, therapy with metronidazole was considered unnecessary if piperacillin-tazobactam, which has activity against anaerobic bacteria, was administered.
Adequacy of GNC Assessment
For patients with any gram-negative pathogen identified, adequacy of antibiotic coverage was adjudicated by an independent, blinded panel of 3 external experts in antimicrobial therapy and critical care after the ATTAIN studies had concluded. Culture results and susceptibilities were compared with the actual drugs administered. The decision whether therapy was adequate or inadequate was based on a majority vote. Gram-negative therapy was considered inadequate if the patient (1) never received antibiotic(s) with in vitro activity covering all gramnegative pathogens isolated at baseline or (2) did not receive concomitant antibiotic(s) with in vitro activity covering all gram-negative pathogens isolated at baseline until study day 3 or later. The appropriateness of concomitant antibiotic dosing was not assessed by the panel.
GNC Group Analysis
The effect of identified gram-negative pathogen(s) and the adequacy of empiric GNC on 28-day mortality and clinical outcomes in 3 patient groups were analyzed and compared. Group 1, patients with gram-positive-only infection (GPO) received adequate empiric gram-positive coverage based on known activity of telavancin or vancomycin. There was no potential confounding from gram-negative infections or inadequacy of GNC in this group. Group 2 included patients with GPO plus those with mixed infection and adequate GNC, receiving adequate empiric gram-positive coverage and GNC. Empiric concomitant gram-negative antibiotic coverage was determined to be adequate in an independent blinded review. Adequate empiric gram-positive coverage was based on known activity of telavancin or vancomycin. Finally, group 3 included patients with gram-negative-only infection (GNO) plus those with mixed infection receiving inadequate GNC. Empiric concomitant gram-negative antibiotic coverage was determined to be inadequate in an independent blinded review. There was no GNC for either telavancin or vancomycin.
Statistical Analysis
Baseline gram-negative pathogens and clinical response were summarized for the AT analysis population. Estimate of clinical response for each treatment group was calculated as the number of patients with a "cure" response relative to the total number of patients. Confidence intervals (CIs) for the differences in clinical response were calculated using a normal approximation without continuity correction. If any cell size is <10, as might occur during a subgroup analysis, the CIs were calculated using the adjustment presented by Agresti and Caffo [5] to adjust for the sparse cell size. Cause of death and 28-day mortality were evaluated in the safety population. Incidence of mortality and treatment differences (telavancin minus vancomycin), including 2-sided 95% CIs, were evaluated using Kaplan-Meier estimates.
RESULTS
In the AT population, the overall proportion of patients with a gram-negative pathogen was 37.4% (562 of 1503). This included patients with mixed gram-negative infections that were adequately treated (7.3%; 109 of 1503), mixed gram-negative infections that were inadequately treated (10.7%; 161 of 1503), and infections in which a gram-negative pathogen was the only pathogen isolated (19.4%; 292 of 1503). The overall proportion of patients with gram-negative infections that were inadequately treated and GNO infections (GNO plus mixed infections with inadequate GNC) was 30.1% (453 of 1503), with 32.0% in the telavancin group and 28.3% in the vancomycin group.
Piperacillin-Tazobactam Use
Piperacillin-tazobactam was used early in the course of treatment (within the first 3 days) for coverage of HABP/VABP in 93 of 751 patients (13%) in the telavancin group and 88 of 752 patients (12%) in the vancomycin group. Three and 2 subjects in these treatment groups, respectively, received piperacillintazobactam early in their course for other indications. Piperacillintazobactam was started on day 4 or later in 73 of 751 (10%) and 54 of 752 (7%) patients in the telavancin and vancomycin groups, respectively. Twelve and 10 subjects, respectively, had piperacillin-tazobactam initiated on or after day 4 in each treatment group for other indications.
Frequency of Baseline Gram-Negative Pathogens by Adequacy of Coverage
As shown in Table 1 , the most frequently observed gramnegative pathogens in the ATTAIN studies were Pseudomonas spp., Acinetobacter spp., and Klebsiella spp. Collectively these accounted for 61.5% (434 of 706) of all gram-negative pathogens recovered from blood or respiratory tract samples.
Slightly more patients with ≥1 gram-negative pathogen at baseline were identified in the telavancin group than in the van Cause of Death at Day 28 by Adequacy of GNC Table 2 reviews the primary cause of death by adequacy of GNC. When considering infectious-related deaths (sepsis/shock, multiorgan failure, and nosocomial pneumonia), mortality for telavancin was almost double that of vancomycin for those with GNO plus mixed inadequate GNC (12.9%, telavancin; 6.6%, vancomycin). Kaplan-Meier 28-day mortality curves for each GNC group illustrate the impact that gram-negative infections and inadequately treated gram-negative infections have on mortality for telavancin compared with vancomycin (see Figure 1) .
Clinical Efficacy and Mortality by Adequacy of GNC
Clinical efficacy and 28-day all-cause mortality summarized by treatment and adequacy of GNC are shown in Table 3 . When considering the GNO plus mixed inadequate GNC group, in which a successful outcome would not be expected based on telavancin or vancomycin activity, mortality rates (Kaplan-Meier estimates) were numerically higher in the telavancin group for this subset (telavancin, 24.5%; vancomycin, 21.6%; treatment difference, 2.9% [95% CI, −4.9% to 10.8%]). In contrast, in the subset of patients with GPO infections, mortality was numerically lower for telavancin (telavancin, 23.1%; vancomycin, 25.2%; treatment difference, −2.1% [−9.5% to 5.3%]). Moreover, numerically higher clinical response rates were observed for telavancin in the GPO group (telavancin, 66.3%; vancomycin, 60.8%; treatment difference, 5.5% [−2.7% to 13.7%]) and in the GPO plus mixed adequate GNC group (telavancin, 61.4%; vancomycin, 58.4%; treatment difference, 3.0% [−4.7% to 10.6%]).
Comparing the number of deaths observed for the overall ATTAIN safety population (telavancin, 179 of 751; vancomycin, 163 of 752; difference, 16 deaths), 13 of these 16 deaths were observed for telavancin in the GNO plus mixed inadequate GNC group (telavancin, 58 of 751; vancomycin, 45 of 752); 9 of the 13 deaths for telavancin were in the GNO group, with the remaining 4 in the mixed inadequate GNC group. The KaplanMeier curve for the GNO plus mixed inadequate GNC group shows that the difference in mortality rates between telavancin and vancomycin was apparent after study day 2 (see Figure 1D) .
Consistent with the boxed warning in the telavancin product labeling of increased mortality risk observed in patients with reduced renal function [1] , the difference of 13 deaths noted above could be accounted for by patients with an estimated CrCl <50 mL/min; of particular note, all of the 13 deaths were observed in patients whose estimated CrCl was <30 mL/min (telavancin, 20 of 32; vancomycin, 7 of 27).
DISCUSSION
Telavancin was shown to be clinically efficacious in the management of HABP and VABP caused by gram-positive bacterial pathogens in 2 methodologically identical, controlled clinical trials [2] . In this post hoc analysis from the ATTAIN trials, we demonstrate the impact of gram-negative organisms and adequacy of GNC on clinical outcomes, including clinical response and 28-day mortality in studies designed to evaluate agents for gram-positive infections. From a clinical standpoint, the impact of initially appropriate therapy on outcomes in HABP and VABP is well established [6, 7] .
In the ATTAIN trials, patients with mixed infections could have received telavancin or vancomycin plus either aztreonam or piperacillin-tazobactam (initially) for the gram-negative component of their pneumonia. Aztreonam was selected owing to its lack of gram-positive activity to avoid any possibility of influencing the gram-positive activity of the drugs under study. Unfortunately, in many patients the gram-negative pathogens identified were not susceptible to either aztreonam or piperacillin-tazobactam because the most common pathogens were multidrug-resistant organisms, such as Pseudomonas aeruginosa or Acinetobacter spp. A similar confounding effect was observed in a catheter-related bloodstream infection registration study comparing linezolid and vancomycin, using the presence of gram-negative pathogens at baseline that were either not treated or inadequately treated as a predictor of mortality [8] . f Including Achromobacter (n = 5), Burkholderia (n = 4), Chryseobacterium (n = 3), Empedobacter (n = 1), Fusobacterium (n = 1), Hafnia (n = 1), and Providencia (n = 5) species.
In the ATTAIN trials, patients were required to meet specified inclusion and exclusion criteria to qualify for enrollment, which were primarily clinical criteria. Despite an enrollment requirement for gram-positive organisms present on Gram stain of respiratory secretions (eg, together with gram-negative organisms), cultures could have been reported to be growing only gram-negative organisms. In addition, stratification based on Gram stain results ( predominance of gram-positive vs gram-negative organisms) was not conducted. For these reasons, despite randomization, patients with gram-negative infections were unevenly allocated between the telavancin and vancomycin groups in these studies.
Although the overall difference in 28-day all-cause mortality is only 2% between telavancin and vancomycin, it is important to investigate potential contributing factors [1] . One hypothesis was whether there was any telavancin-associated antagonism of gram-negative therapy. Studies in animal models (unpublished data), checkerboard microbiologic studies [9] , and studies in healthy subjects [10] showed that there was no pharmacokinetic/pharmacodynamic interference when combining telavancin and aztreonam or piperacillin-tazobactam. Another hypothesis was that renal disease adversely affected telavancin activity. This, too, was shown not to be the case, with no loss in biologic activity for telavancin in patients with impaired renal function [11] .
As shown in this analysis of 28-day all-cause mortality of the ATTAIN clinical trials, the number of patients in the group of GNO plus mixed infection with inadequate GNC, based on limitations in allowed concurrent antibiotic therapy, contributed to the higher mortality differences observed between telavancintreated and vancomycin-treated patients. In fact, we have shown that most of the difference in number of deaths between telavancin and vancomycin in the ATTAIN trials (13 of 16 additional deaths) may be accounted for by the number of deaths in the GNO infections (n = 9) and mixed infections with inadequate GNC (n = 4) groups, and these were all shown to be infection related (as shown in Table 2 ). The mortality rates were similar among patients with solely gram-positive pathogens plus mixed infections with adequate GNC.
There are several limitations associated with the results reported in this article. First, all of the analyses were post hoc that involved small subsets (<40% of the overall AT population), and the adequacy of gram-negative treatment was determined after the study was concluded, although this was done by a blinded independent expert panel. Second, the appropriateness of concomitant antibiotic dosing was not assessed, and this factor may have influenced observed clinical efficacy in the different GNC groups that were evaluated. Third, as mentioned earlier, randomization was not stratified by gram-negative b Including all patients, whether or not a pathogen was identified.
c Total infection-related deaths include deaths from sepsis/shock, multiorgan failure, and nosocomial pneumonia.
infection and adequacy of gram-negative treatment, which resulted in treatment imbalances and possibly other imbalances in risk factors that were not accounted for. Finally, it is possible that some gram-negative pathogens identified in the ATTAIN trials were colonizers and did not cause actual infection. Although this was not formally assessed in the ATTAIN studies, the inclusion/exclusion criteria were designed to enhance the probability of enrolling patients with true infections. The observed confounding by inadequately treated gram-negative infection does not account for all of the mortality differences seen in the ATTAIN clinical trials. Hence, there remains a degree of mortality risk among patients with pre-existing renal Abbreviations: CI, confidence interval; GNC, gram-negative coverage; GNO, gram-negative-only; GPO, gram-positive-only. a The all-treated population, including 2 patients who were randomized to receive vancomycin but received telavancin; their findings are reported for vancomycin.
b The safety population, including 2 patients who were randomized to receive vancomycin but received telavancin; their findings are reported for telavancin.
c Including all patients, whether or not a pathogen was identified.
dysfunction [3] . Therefore, caution should be exercised according to the approved product labeling and a benefit:risk assessment performed when evaluating use of telavancin in such patients. Based on this post hoc analysis of the ATTAIN HABP/VABP trials, it was shown that the evaluation of clinical efficacy and 28-day mortality rates could be influenced by more patients with gram-negative pathogens at baseline in the telavancin groups and by inadequate treatment of these gram-negative infections. Considering patients with GPO infections, patients receiving telavancin had numerically higher clinical cure rates and similar mortality rates at 28 days compared with patients receiving vancomycin.
Notes
